Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biotron ( (AU:BIT) ) just unveiled an announcement.
Biotron Limited has confirmed that its recent capital raising under a prospectus dated 18 November 2025 is now fully subscribed, with the company issuing 292,666,664 new shares and 146,333,324 attaching options (BITO, exercisable at $0.02 and expiring 24 November 2027) as shortfall securities. The board has also noted the appointment of Dr Paul Kasian as a director effective 23 December 2025, and stated that the matters disclosed in this supplementary prospectus are not considered materially adverse for investors, meaning no withdrawal rights will be offered, thereby solidifying the company’s capital structure and governance as it proceeds with its planned activities.
The most recent analyst rating on (AU:BIT) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Biotron stock, see the AU:BIT Stock Forecast page.
More about Biotron
Biotron Limited is an Australian biotechnology company listed on the ASX, focused on developing and commercialising therapeutic products, particularly in the antiviral and related biomedical fields.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.43M
See more data about BIT stock on TipRanks’ Stock Analysis page.